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these potential chronic damages is vascular damage 
caused by early atherosclerosis. According Urowitz 
et al (1976), the distribution of death causes in SLE 
was bimodal where the early death was caused by 
the disease severity or infection, while the late cause 
was cardiovascular reasons.2 Young women with 
SLE have fi ve times more risk for a cardiovascular 
event compared with normal control on the same 
age. This risk increases with age, disease duration, 
hypertension, dyslipidemia, body mass index, 
and CRP.3,4 In a cohort study on 78 SLE patients 
without atherosclerosis signs, after fi ve years there 
were increased thickness on 28% patients and 
atherosclerotic plaque on 17% patients.5 Traditional 
risk factors could not explain the early pathogenesis 
of atherosclerosis in SLE, so it was postulated 
that autoimmune processes causing chronic 
infl ammation was the main contributor. 6,7 Vascular 
complications in SLE should have enough attention 
because the process happens even before symptoms 
could appear.8 Peripheral arterial disease (PAD) 
is one example of these vascular complications. 
PAD usually asymptomatic and does not have 
classical symptoms that it hinders early diagnosis.9 
It became the cause of decreased quality of life in 
more than two millions of patients in USA, which 
affected morbidity, mortality, and increased health 
spending.10 SLE patients (mean age 39 years old) 
were reported having prevalence of abnormal ankle-
brachial index (ABI) higher than normal population 
(37% vs 4%)11 The effect of disease duration on the 
increasing event of PAD in SLE patients have not 
been studied enough. A few of studies overseas 
such as Burgos et al (LUMINA, 2009) 12 in USA, 
Bhatt et al (2007)13 in India, and Wang et al (1993)14 
in China did not give adequate explanation on the 
relationship between the duration of SLE and this 
complication. In Indonesia, Sari RM (2009) did a 
study measuring the thickness of medial intima in 
the carotid artery of women younger than 40 years 
old with SLE. The study reported the prevalence of 
atherosclerosis about 40%, with duration of disease, 
age, and duration of steroid therapy were the factors 
with positive correlation.15 Compared with USG, 
ABI was cheaper and easier for screening because 
of its good sensitivity and specifi city.16
ABSTRACT 
Background: Peripheral arterial disease is a chronic 
complication that affects morbidity and mortality in SLE 
patient. However, there were only a few of researches 
studying the relationship of disease duration and 
peripheral arterial disease event overseas and it has 
never been studied in Indonesia. 
Objectives: To obtain information about the increased 
event of peripheral arterial disease in women of 40 years 
old or younger with SLE’s duration of five years or longer 
compared with less than five years.
Methods: This was a case control study conducted 
between June - August 2012 at Cipto Mangunkusumo 
hospital, Jakarta. Subjects were women of 40 years 
old or younger with SLE who visited Rheumatolgy and 
Allergy-Immunlogy outpatient clinic. They were assigned 
to case and control groups and traced retrospectively 
using interview and medical record. The relationship 
between disease duration and peripheral arterial disease 
was estimated using OR and the role of confounding 
factors was analysed using logistic regression one by 
one, resulted in fully adjusted OR.
Results: A total of 90 subjects were recruited, 18 
subjects in case group and 72 subjects in control group. 
Traditional risk factors were similiar in both groups. In 
multivariat analysis, there was a relationship between 
disease duration 5 years or longer and peripheral arterial 
disease with fully adjusted OR 1,9 (95%CI 0,575-6,543). 
Older age and steroid therapy were the confounding 
factors. 
Conclusion: There was an increased event of peripheral 
arterial disease in women of 40 years old or younger 
with SLE’s duration five years or longer compared with 
subjects having the disease duration less than five years, 
but this increase was not statistically significant. 
Keywords: Peripheral arterial disease, lupus 
erythematosus systemic, disease duration
The fast development of medical technology 
affects the life expectancy of people with SLE.1 
But this increase of life expectancy brings new 
challenges as the patients will have complications 
associated with the accumulation of chronic 
damage on organs. Without early detection and 
promp treatment, there will be decreased quality of 
life with increased morbidity and mortality. One of 
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METHODS
Study design and subjects
This study was done in Rheumatology and Allergy-
Immunology outpatient clinic in Cipto Mangunkusumo 
Hospital Jakarta between June-August 2012. The samples 
were taken consecutively and there were 104 subjects eligible 
for the study, which means they were SLE patients (diagnosis 
according to the revised ACR criteria in 1997) and younger 
than 40 years old. 14 subjects were excluded because 8 of them 
had mixed connective tissue disease, 5 refused to be included 
in the study, and the other was in her 26 weeks of pregnancy. 
After interview, medical record tracking, and physical 
examination, these 90 subjects had their ankle brachial index 
measured using ABI osilometry by one examiner in Endocrine 
and Metabolic outpatient clinic in Cipto Mangunkusumo 
Hospital. Subjects with ABI 0.9 or lower and more than 1.3 
were put in the case group (peripheral arterial disease) and 
those with ABI of 0.9-1.3 were put in the control group.
All of the subjects were interviewed using the same 
questionnaire. The duration of disease was determined using 
the data from interview and medical records. Disease activity 
was assessed using Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI). Any history of hypertension, DM, 
dyslipidemia, organs involvement, and therapy was taken 
from interview and medical records. Subjects with essential 
hypertension and DM before diagnosis of SLE were excluded.
Data analysis 
Data analysis was done with SPSS ver. 16.0.0., using p-value 
less than 0.05 and CI of 95%. The relation of disease duration 
with PAD incidence was estimated in OR. Multivariat analysis 
were done using regression logistic resulted in fully adjusted 
OR, which was the value after analyzing the confounding 
factors.
RESULTS
Subjects characteristics
During the study period, there were 104 patients who came 
to Rheumatology and Allergy-Immunology outpatient clinic 
eligible for study subjects, but 14 patients were excluded 
leaving 90 subjects. 18 subjects were put into the case group 
and 72 subjects were put into the control group. The study was 
terminated before it had enough samples because there were 
not enough patients and limited time period. To expand the 
number of samples, the authors tried national registry of lupus 
patients, but a lot of the data were invalid.
Table 1 shows the characteristics of study subjects. The 
mean age was similar in both groups, which was 29.8 years 
old in the case group and 29 years old in the control group. 
Subjects in the case group had longer mean duration of disease 
than control group.
Table 1. Subjects characteristics
Characteristics Case
(n=18)
Control
(n=72)
p Value
Mean age (years), SD 28.83 (  8.20) 29    (  6.62) --
Duration of disease (months), SD 57      (  3-178) 44.5 (  1-260) 0.79
Mean BMI (SD) 22.1   (  3.74) 21.5 (  2.95) --
Hypertension (%)   1      (  5.6%)   3    (  4.2%) 0.80
Diabetes Mellitus (%)   0   2    (  2.7%) 0.48
Dyslipidemia   7      (38.9) 23    (31.39) --
Kidney involvement   9      (50%) 28    (38.8%) 0.39
Mean disease activity score (SD)*   4.4   (  3.05)   4    (  3.68) --
Chloroquine therapy   8      (44.4%) 20    (27.8%) 0.28
Steroid therapy 17      (94.4%) 71    (98.6%) --
Mean duration of steroid therapy (months), SD 55.7   (41.17) 43    (45.21) 0.68
*disease activity score was assessed using Mex-Sledai, SD = Standard deviation, 
Subjects in the case group had longer mean duration 
of disease than the control group. Both BMI and disease 
activity score in the two groups were similar. Traditional risk 
factors for atherosclerosis such as diabetes, hypertension, and 
dyslipidemia were also similar in both groups. There was no 
history of smoking and previous cardiovascular events in 
the groups. Kidney involvement happened more in the case 
group than control group. There were 2 subjects with diabetes 
mellitus in the control group, and it was because of steroid 
therapy. Chloroquin was more frequently used in case group 
while steroid was used by a lot of subjects in both groups.
The effect of disease duration on the incidence of 
peripheral arterial disease
Table 5.2 shows increased risk of PAD in subjects with 
duration of disease ≥5 but this increase is not signifi cant 
statistically (crude OR 1,6 (CI 95% 0,559-4,576); p=0,38). 
This relation did not change after adding confounding factors 
such as chloroquine therapy, age, steroid therapy, proteinuria, 
disease activity score, dyslipidemia, and hypertension using 
logistic regression. The fi nal result was fully adjusted OR 1.9 
(CI 95% 0,575-6,543).
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Table 2. Multivariate analysis of disease duration and its effect on 
PAD incidence after including confounding factors.
Variable OR CI 95% P
Duration of disease
Crude OR 1.6 0.559-4.576 0.38
Adjusted OR
Chloroquine 1.5 0.511-4.348 0.46
Age 1.9 0.589-5.852 0.29
Steroid therapy 2.1 0.643-6.914 0.21
Proteinuria 1.9 0.595-6.557 0.26
Disease activity score 1.9 0.569-6.387 0.29
dyslipidemia 1.9 0.575-6.512 0.28
Hypertension (fully adjusted) 1.9 0.575-6.543 0.28
DISCUSSION
Demographic characteristics
In this study, the mean age on the case group was 28.83 
years old (SD 8,2) and 29 years old on the control group (SD 
6,62). The mean age in this study did not differ far from other 
studies such as Bhatt et al (2007) in India with mean age of 
30.7 (SD 8,7).13 But there were studies with older mean age, 
such as LUMINA (2009), a study with multiethnic samples in 
USA with mean age of 36,5 years old, while Liu et al (2009) in 
China reported mean age around 33,1 years old (SD 11,8).12,17 
Cardiovascular incidence in women without SLE were more 
common after 55 years old, but the same principle did not 
happen with the SLE group. Manzi et al did an epidemiologic 
study and reported that women with SLE between 35-44 years 
old had 5 times risk of cardiovascular incidence compared 
with the same age group without SLE.3 Most of the subjects on 
both groups were jobless or housewives with moderate level 
of education (highschool). This affected their social economic 
status and their view about SLE. Most of the subjects had 
insurance so program such as routine examination, laboratory 
workups, and treatment choice depended on their insurance 
cover. Besides, a lot of patients lived outside Jakarta, or when 
they lived in Jakarta, they were far from the hospital. These 
affected their compliance for routine control or following 
treatment program.
Clinical characteristics
The subjects in case group tended to had longer duration of 
disease (57 months) compared with those in the control group 
(44.5 months). McDonald did a study in USA and Liu did too 
in China, they both reported longer duration of disease (112 
months and 99 months). 12,17 But Bhatt in India reported shorter 
duration of disease with 49.4 months.13 This variation was 
most probably caused difference in ethnicity and treatment. 
Traditional risk factors of atherosclerosis in both groups were 
similar. This fi nding was in accordance with previous studies. 
These traditional risk factors could not specifi cally explain the 
pathogenesis of early atherosclerosis in SLE and were not the 
primary causes.18,19 
Subjects in the case group had more kidney involvement. 
Proteinuria is one of many factors causing early atherosclerosis 
in SLE, because it stimulates apolipoprotein and cholesterol 
synthesis in liver, resulting in hypercholesterolemia as a risk 
factor for atherosclerosis.20 
Disease activity assessment using Mex-SLEDAI score 
showed both groups was in their active phase with mean value 
of 4.4 (SD 3.05) in the case group and mean value of 4 (SD 
3.68) in the control group. This was similar with a study by 
Sari (2009) involving SLE women in Cipto Mangunkusumo 
Hospital as her subjects. Her study reported disease activity 
score of 3.15. High scores of disease activity were probably 
due to low compliance in treatment. This condition might 
be caused by low awareness affected by education level, 
economy level, and living places far from the hospital. 
Most of the subjects in both groups had steroid as their 
main therapy, but one subject in each group did not have 
steroid. These subjects had mucocutaneous SLE and they 
were given chloroquine as main treatment. Those with steroid 
had it for long duration (more than 1 year), but mean duration 
of steroid therapy in control group was longer (55.7 months, 
SD 41.17) than in case group (43 months, SD 45.21). Long 
duration of steroid therapy was probably related to kidney 
involvement and high disease activity score. 
The effect of disease duration on the incidence of PAD
Urowitz et al (1976) was the fi rst to report that the late cause 
of death in SLE was secondary to cardiovascular disorder. 
The risk of cardiovascular incidence increased every year 
according to duration of SLE. Young women with SLE have 
fi ve times more risk to experience cardiovascular incidence 
compared with their normal counterparts. This is caused by 
early atherosclerosis in SLE. Traditional risk factors such as 
hypertension, dyslipidemia, diabetes mellitus, obesitas, and 
sedentary life style have important roles in its formation, but 
a number of studies have proven that even after these risk 
factors were modifi ed, those with SLE still have higher rate 
of cardiovascular incidence. Disease duration, high score 
of disease activity, kidney involvement, steroid therapy, 
chloroquine therapy, antiphospholipid antibody, and CRP 
are some factors related to the early atherosclerosis in 
SLE.2 Analysis with logistic regression in this study showed 
clinically signifi cant relation between the duration of disease 
with incidence of PAD (OR 1.9, CI 95% 0,559-4,576), but 
it was not signifi cant statistically (p=0,37). This was caused 
by low number of samples, low power of study (<80%), and 
wide confi dence interval. On the early estimation of samples, 
we assumed high OR (4), but in reality the OR estimated in 
the end was far below, and one of the reason the study was not 
clinically signifi cant. After re-estimation, for power study of 
80% the samples needed for both groups were 136 samples 
each. For the ratio of case : control 1:4, the study needed 85 in 
case group and 340 in control group. 
OR value of 1.9 was clinically signifi cant because the 
effect of PAD was signifi cant in a patient’s morbidity and 
mortality.four times more likely to die in ten years compared 
with patients without PAD.21 
All subjects in case group were asymptomatic PAD with 
ABI <0.9. Low ABI (<0.9) in asymptomatic patients is related 
with morbidity and mortality. It also plays a role as biomarker 
in cardiovascular incidence. Asymptomatic PAD is related 
to decreased function of lower extremities in women older 
than 65 years old. 22 Asymptomatic PAD is also related to an 
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increase by 1.4 in total mortality and 1.5 increase of mortality 
with cardiovascular causes.23 A systematic review involving 
28,679 subjects reported consistent relationship between 
low ABI (<0.9) with prognosis of cardiovascular incidence. 
The specifi city of low ABI (<0.9) in detecting coronary 
heart disease, stroke, and mortality caused by cardiovascular 
incidence were 92.7%, 92.2%, and 87.8% with positive 
likelihood ratio of 2.53, 2.45, and 5.61.24 
The role of confounding variable in the relation between 
duration of disease and PAD incidence 
In multivariate analysis using logistic regression, there were 
potential confounding variables consisted of age and duration 
of steroid therapy. These variables became the confounding 
variable because they changed OR value more than 10%, in 
which age changed adjusted OR for 24.5% and duration of 
steroid therapy changed adjusted OR for 13.5%. A few of 
studies reported the same result where age was a variable 
affecting PAD incidence in SLE.12,17 Age can not be separated 
from disease duration, because longer disease duration means 
older age. Unlike patients without SLE, PAD in SLE happens 
early with increasing risk factors in accordance to the patient’s 
increasing age. 
The effect of steroid therapy on cardiovascular incidence 
in SLE is still controversial. Treatment using steroid is a 
dilemma. Inadequate treatment leaves room for infl ammation 
as a trigger for early atherosclerosis, but long duration of 
steroid increases risk of dyslipidemia and hypertension as risk 
factors of atherosclerosis. Increased prednisone dose up to 10 
mg/ day is related to the increase of cholesterol level by 7.5 
mg/dl (SE 1.46) and increased mean arterial pressure by 1.1 
mmHg.25 McDonald et al reported duration of steroid therapy 
as a risk factor for PAD in SLE patients (p<0.05) in which case 
group received steroid for 109 months compared with control 
group (34 months). The mean daily dosage for case group was 
14 mg/ day and 15 mg/ day for control group.26 But Liu et al in 
their study about risk factors of digital gangrene in SLE patient 
stated that steroid did not have any role (p=0.10).17 More 
than 5 years of steroid therapy is related with calsifi cation on 
peripheral blood vessel and more severe clinical symptoms of 
PAD. 26 Because steroid effect is still controversial, confi rming 
direct effect of steroid on PAD incidence needs further study. 
Study limitation
One of limiting factors in this study was low number of 
samples, resulting in low power of the study (<80%). Low 
power made it diffi cult to gain statistically signifi cant results. 
Other limiting factors were no measurement of infl ammation 
factors and level of antibody anticardiolipin because of the 
limited fund and no reference on normal ABI of Indonesian.
Recall bias is a limitation in case control study, but 
in this study there were medical records to keep track of 
disease duration. With multivariate analysis, recall bias and 
confounding bias effects could be minimalized. Because there 
were no data about SLE population (study base), control group 
recruitment could not represent common population of SLE 
because they were taken from those coming to the hospital to 
get treatment, resulting in uncontrolled selection bias. 
Study result generalization 
In order to apply this study result to a wider population, the 
validity of this study needs to be assessed. Internal validity I 
of this study is good because there was no drop out subjects 
and all subjects had complete data about their risk factors. 
Internal validity II is not good enough because subjects in 
the control group were taken from patients who came to the 
hospital, causing selection bias and low representative power. 
CONCLUSION
There was an increase of PAD incidence in SLE women aged 
<40 years old with SLE >5 years compared with <5 years, but 
it was not statistically signifi cant.
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